Alnylam CEO, John Maraganore, Named BIO Chair for 2017-2018 Term
June 19 2017 - 4:00PM
Business Wire
Alnylam Pharmaceuticals, Inc. (Nasdaq:ALNY), the leading RNAi
therapeutics company, today announced that Chief Executive Officer
John Maraganore, Ph.D., has been elected as the Chair of the
Biotechnology Innovation Organization (BIO) Board of Directors for
the 2017-2018 term.
“BIO has long supported the innovative, transformative work of
the biotech community, and it is an honor to serve as Chair for
this organization that continues to drive innovation across
healthcare, agricultural, industrial and environmental
biotechnology products, while continuing my leadership of Alnylam,”
said Dr. Maraganore. “I’ve devoted my life’s work to the biotech
industry and believe that it is one of the most powerful examples
of what can be accomplished when people work together to solve
problems for the benefit of all of humanity. I look forward to
working with industry leaders, government, patient groups,
physicians and stakeholders around the globe to advance BIO’s
mission while addressing some of our industry’s most exciting
opportunities and most pressing issues.”
BIO is the world's largest trade association representing
biotechnology companies, academic institutions, state biotechnology
centers and related organizations across the United States and in
more than 30 other countries. Dr. Maraganore has served on the
board since 2006. He has held roles on the Executive Committee,
served as co-chair of the Regulatory Environment Committee and
previously served as chair of the Emerging Company Section. Dr.
Maraganore will serve as BIO chair through June 2018, when he will
be eligible for re-election for another one-year term.
“John Maraganore has been an active member and engaged leader of
BIO for more than a decade. As an industry veteran and pioneering
leader within the biotech community, I am confident he will advance
the mission of BIO and our industry at large,” said Jim Greenwood,
president and chief executive officer of BIO. “I look forward to
working closely with John to ensure the continued success of
BIO.”
About Alnylam Pharmaceuticals
Alnylam (Nasdaq: ALNY) is leading the translation of RNA
interference (RNAi) into a whole new class of innovative medicines
with the potential to transform the lives of patients who have
limited or inadequate treatment options. Based on Nobel
Prize-winning science, RNAi therapeutics represent a powerful,
clinically validated approach for the treatment of a wide range of
debilitating diseases. Founded in 2002, Alnylam is delivering on a
bold vision to turn scientific possibility into reality, with a
robust discovery platform and deep pipeline of investigational
medicines, including three product candidates that are in
late-stage development or will be in 2017. Looking forward, Alnylam
will continue to execute on its "Alnylam 2020" strategy of building
a multi-product, commercial-stage biopharmaceutical company with a
sustainable pipeline of RNAi-based medicines. For more information
about our people, science and pipeline, please
visit www.alnylam.com and engage with us on Twitter at
@Alnylam.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170619005595/en/
Alnylam Pharmaceuticals, Inc.Investors and MediaChristine
Regan Lindenboom, 617-682-4340orInvestorsJosh Brodsky,
617-551-8276
Alnylam Pharmaceuticals (NASDAQ:ALNY)
Historical Stock Chart
From Mar 2024 to Apr 2024
Alnylam Pharmaceuticals (NASDAQ:ALNY)
Historical Stock Chart
From Apr 2023 to Apr 2024